Ester Sánchez-Tilló

Sobre mí

Publicaciones destacadas

• The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas

  Autores:

  Sanchez-Tillo, Ester; Pedrosa, Leire; Vila, Ingrid; Chen, Yongxu; Gyorffy, Balazs;

  (...)

  Darling, Douglas S; Cuatrecasas, Miriam; Castells, Antoni; Maurel, Joan; Postigo, Antonio.

  Ver listado completo de autores

  Referencia: Jci Insight 2023.

• ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1

  Autores:

  de Barrios, Oriol; Gyorffy, Balazs; Jesus Fernandez-Acenero, Maria; Sanchez-Tillo, Ester; Sanchez-Moral, Lidia;

  (...)

  Roue, Gael; Casal, Jose I; Darling, Douglas S; Castells, Antoni; Postigo, Antonio.

  Ver listado completo de autores

  Referencia: Gut 2017.

• ZEB1 and TCF4 reciprocally modulate their transcriptional activities to regulate Wnt target gene expression

  Autores:

  Sanchez-Tillo, E; de Barrios, O; Valls, E; Darling, D S; Castells, A;

  Postigo, A.

  Referencia: Oncogene 2015.

• The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma

  Autores:

  Sanchez-Tillo, E; Fanlo, L; Siles, L; Montes-Moreno, S; Moros, A;

  (...)

  Martinez, A; Colomer, D; Gyorffy, B; Roue, G; Postigo, A.

  Ver listado completo de autores

  Referencia: Cell Death And Differentiation 2014.

• Rb1 family mutation is sufficient for sarcoma initiation

  Autores:

  Liu, Yongqing; Sanchez-Tillo, Ester; Lu, Xiaoqin; Clem, Brian; Telang, Sucheta;

  Jenson, Alfred B; Cuatrecasas, Miriam; Chesney, Jason; Postigo, Antonio; Dean, Douglas C.

  Referencia: Nature Communications 2013.

• Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and Then Ras Proteins Are Required for Tumor Initiation and Progression

  Autores:

  Liu, Yongqing; Sanchez-Tillo, Ester; Lu, Xiaoqin; Huang, LI; Clem, Brian;

  (...)

  Jenson, Alfred B; Cuatrecasas, Miriam; Chesney, Jason; Postigo, Antonio; Dean, Douglas C.

  Ver listado completo de autores

  Referencia: Journal Of Biological Chemistry 2013.

• ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1

  Autores:

  Sanchez-Tillo, Ester; de Barrios, Oriol; Siles, Laura; Amendola, Pier G; Darling, Douglas S;

  Cuatrecasas, Miriam; Castells, Antoni; Postigo, Antonio.

  Referencia: Clinical Cancer Research 2013.

• EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness

  Autores:

  Sanchez-Tillo, Ester; Liu, Yongqing; de Barrios, Oriol; Siles, Laura; Fanlo, Lucia;

  Cuatrecasas, Miriam; Darling, Douglas S; Dean, Douglas C; Castells, Antoni; Postigo, Antonio.

  Referencia: Cellular And Molecular Life Sciences 2012.

• β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness.

  Autores:

  Sanchez-Tillo, Ester; de Barrios, Oriol; Siles, Laura; Cuatrecasas, Miriam; Castells, Antoni;

  Postigo, Antonio.

  Referencia: Proceedings Of The National Academy Of Sciences Of The United States Of America 2011.

Proyectos destacados

• Plataforma ISCIII de Biomodelos y Biobancos. Fortalecimiento del Biobanco, acreditado con la nueva norma ISO 20387:2020 de biobancos, para la optimización del catálogo de muestras y datos asociados, y ampliación de biomodelos en organoides para la transferencia a la biomedicina

  Financiador: ISCIII (Programa financiador competitivo)

  Código: PT23/00124

  Duración: 01/01/2024

• GRAIL/RNF128 E3 ligase in colon cancer subtypes with KRAS, BRAF, and APC mutations

  Investigador/a principal: Ester Sánchez Tilló

  Financiador: ISCIII (Instituto de Salud Carlos III)-Subdireccion General de Evaluacion

  Código: PI18/00244

  Duración: 01/01/2019 - 31/12/2021

• ZEB1 role in oncogenic transformation and tumorigenesis of CRC by Wnt, KRas and Braf pathways

  Investigador/a principal: Ester Sánchez Tilló

  Financiador: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (Sede o evento); Universidad Complutense de Madrid

  Código: CP13/00200

  Duración: 31/01/2014 - 31/01/2017

• Characterization of ZEB1/microRNA pathway as a prognostic biomarker of metastatic ability of colorectal carcinomas and their chemoterapeutic response. Validation of ZEB1 as a potential therapeutic target

  Financiador: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (Sede o evento); Acadèmia de Ciències Mèdiques de Catalunya i de Balears

  Duración: 01/04/2013 - 31/05/2015

• Identification of gene expression profiles regulated by the microRNA/ZEB1-ZEB2 pathway and its role in the invasive and metastatic behavior of breast tumors and their response to treatment.

  Financiador: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (Sede o evento)

  Duración: 01/09/2012 - 31/12/2013